<DOC>
	<DOC>NCT00197080</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).</brief_summary>
	<brief_title>Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criteria: Diagnosed with RLS using the International RLS Study Group Diagnostic Criteria with a total score of 15 or greater on the International RLS Rating Scale. Have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than 5:00PM. Exclusion criteria: Have secondary RLS. Have any medical conditions that may impact efficacy assessments or that may present a safety concern.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>